Any reason for considering 15% CAGR. Past has been low teens at best.
CDMO business is great but typical Indian companies find it tough to retain global talent. That is a major risk. Syngene operates most out of India. Past track record is patchy. They bought Decision Resources Group in 2012 and sold it in 2020 at about 2x. Decent profit but did not scale as per expectations.
I would put it 1500 cr profits in 2027 at best. With 16x valuations, we get at Mcap of 24000 cr.
That is 50% upside from today’s price.
Valuations are not mouthwatering and there is no MoS.
| Subscribe To Our Free Newsletter |
